Back to top
more

Kodiak Sciences (KOD)

(Delayed Data from NSDQ)

$7.31 USD

7.31
294,275

+0.66 (9.92%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $7.33 +0.02 (0.27%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Kodiak Sciences Inc. (KOD) Up 43.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

EyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease Data

by Zacks Equity Research

EyePoint (EYPT) announces positive top-line data from the phase II study of its investigational candidate, EYP-1901, in the treatment of wet age-related macular degeneration. The stock rallies 178%.

Zacks Equity Research

Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates

by Zacks Equity Research

Kodiak (KOD) reports better-than-expected third-quarter 2023 results and provides updates regarding its pipeline development plans.

Zacks Equity Research

Kodiak Sciences Inc. (KOD) Down 19.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Kodiak (KOD) Q2 Earnings Miss, New Lead Candidate in Focus

by Zacks Equity Research

Kodiak (KOD) reports weaker-than-expected results in second-quarter 2023. The company also provides an update on the status of its pipeline after discontinuing the tarcocimab program.

Zacks Equity Research

Should You Buy Kodiak Sciences (KOD) Ahead of Earnings?

by Zacks Equity Research

Kodiak Sciences (KOD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Ekta Bagri headshot

3 Biotech Stocks Poised to Beat Q2 Earnings Estimates

by Ekta Bagri

We look at a few biotech companies, LEGN, KOD, GRTX, which are poised to beat second-quarter earnings estimates.

Zacks Equity Research

Ligand (LGND) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Ligand's (LGND) second-quarter 2023 performance is likely to have been driven by rising royalty revenues on the back of higher growth in sales of drugs developed using its pelican platform.

Zacks Equity Research

Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Higher demand for its key drugs is likely to have offset generic competition for several drugs and may have boosted Eli Lilly's (LLY) second-quarter sales.

Zacks Equity Research

Biotech Stock Roundup: BIIB, GSK's Q2 Earnings, KOD Faces Setback & More

by Zacks Equity Research

Earnings updates from Biogen (BIIB) and GSK (GSK) are in focus in the biotech sector.

Zacks Equity Research

Kodiak (KOD) Down as Late-Stage DME Studies Fail

by Zacks Equity Research

Kodiak (KOD) stock plunges as it failed to meet the primary endpoint in phase III studies evaluating tarcocimab in diabetic macular edema patients.

Zacks Equity Research

Why Is Kodiak Sciences Inc. (KOD) Up 62.9% Since Last Earnings Report?

by Zacks Equity Research

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Kodiak (KOD) Advances With Tarcocimab Amid Stiff Competition

by Zacks Equity Research

Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of other candidates in the pipeline are concerns.

Zacks Equity Research

Kodiak's (KOD) Q1 Earnings Miss, Pipeline in Focus, Stock Up

by Zacks Equity Research

Despite poor first-quarter performance, Kodiak (KOD) stock rises 13% on the strong pace of the tarcocimab clinical programs.

Zacks Equity Research

Why Is Kodiak Sciences Inc. (KOD) Down 26.3% Since Last Earnings Report?

by Zacks Equity Research

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data

by Zacks Equity Research

Immunic (IMUX) reports positive results from the maintenance phase of the phase II study evaluating its lead candidate, vidofludimus calcium, to treat patients with ulcerative colitis.

Zacks Equity Research

Palisade (PALI) Enrolls First Patient in LB1148 Study in China

by Zacks Equity Research

Palisade's (PALI) development partner, Newsoara, enrolls first patient in the late-stage clinical study of LB1148 to improve postoperative GI function for patients in China.

Zacks Equity Research

InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment

by Zacks Equity Research

InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.

Zacks Equity Research

Kodiak (KOD) Treats First Patient in Diabetic Macular Edema Study

by Zacks Equity Research

Kodiak (KOD) has its first patient in the early-stage study of KSI-501 for treating retinal diseases.

Zacks Equity Research

Kodiak Sciences (KOD) Shares are Up 26% in a Week: Here's Why

by Zacks Equity Research

Shares of Kodiak Sciences (KOD) shot up 26% in the last week after the company announced remaining on track with ongoing studies in its fourth-quarter and full-year 2022 earnings report.

Zacks Equity Research

Kodiak Sciences Inc. (KOD) Up 1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Does Kodiak Sciences Inc. (KOD) Have the Potential to Rally 87% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at an 87.4% upside potential for Kodiak Sciences Inc. (KOD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Wall Street Analysts See a 72% Upside in Kodiak Sciences Inc. (KOD): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 72% upside potential for Kodiak Sciences Inc. (KOD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Kodiak Sciences' (KOD) Q3 Earnings Beat, Eye Candidate in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports a narrower-than-expected loss for the third quarter of 2022. The focus is on the lead candidate, KSI-301, developed for treating various retinal vascular diseases.

Zacks Equity Research

Axsome (AXSM) Q3 Loss Narrower Than Expected, Revenues Miss

by Zacks Equity Research

Axsome (AXSM) reports a narrower-than-expected loss in the third quarter. Revenues comprise sales of the sleep drug, Sunosi, acquired from Jazz.